|
Daehan New Pharm has filed a patent for a method of specifically isolating fibroblasts, accelerating the development of skin improvement treatments
2019.05.28
|
|---|
|
Daehan New Pharm registered a patent for a method to specifically isolate heterogenetic fibroblasts with excellent skin regeneration effects by separating and culturing only those fibroblasts.
Traditional therapies use fibroblasts primarily isolated from dermal tissue behind the ear for treating skin depressions, wrinkles, and refractory dermatitis. However, these treatments are based on mixed fibroblasts, resulting in lower efficacy compared to targeted therapies and cosmetic fillers.
The patented method successfully isolates papillary dermal fibroblasts, located in specific dermal areas, known for high proliferative capacity and a central role in skin aging. Applying these in cell therapies is expected to show superior effects compared to conventional fibroblast treatments.
The “High-purity isolation method for papillary dermal fibroblasts” uses transwell technology to separate highly active papillary dermal fibroblasts from mixed fibroblast populations. Cells isolated with this method showed about seven times higher levels of papillary dermal fibroblast factors and superior proliferative ability. This increase correlates with repeated culturing and maintaining processes.
This purification technology for specific fibroblasts marks Daehan New Pharm's full-scale entry into the cell therapy market. According to Frost & Sullivan, the global cell therapy market is projected to grow at a CAGR of 9.4%, reaching $344 billion by 2021, while the domestic market is growing annually by 25%.
Recently, the Bio Research Center relocated to Osong KBIO and is actively advancing biopharmaceutical development. They have developed a high-efficiency cell culture system for fibroblast therapies and are applying serum-free media from their Japanese partner CSTI in cell therapy development. |


Home